Contenu disponible en anglais seulement.
Bulletin de la Bourse
Bausch + Lomb Corporation (BLCO) inscrit à la Bourse de Toronto
6 mai 2022
| Issuer: | Bausch + Lomb Corporation (the "Company") |
| Security: | Common shares (the "Common Shares") |
| Symbols: | BLCO |
| Issue price per security: | US$18.00 |
| Number of securities issued and outstanding: | 350,000,000 |
| Number of securities reserved for issuance: | 28,000,000 |
| Listing category: | Industrial, Exempt |
| Trading currency: | CDN$ |
| Transaction: | Initial public offering of Common Shares (the "Offering") |
| Listing date: | May 9, 2022 (as at 5:01 p.m.) in anticipation of closing of the Offering |
| Anticipated closing date: | May 10, 2022 (prior to the opening) |
| Posted for trading date: | May 10, 2022 (at the opening) subject to confirmation of closing of the Offering |
| End of trading on an "if, as and when issued" basis: | The Common Shares commenced trading on TSX on an "if, as and when issued" basis on Friday, May 6, 2022. Subject to the closing of the Offering occurring as scheduled prior to the opening of business on Tuesday, May 10, 2022, trading on an "if, as and when issued" basis will conclude at the close of business on Monday, May 9, 2022, unless the Offering closing has been delayed. |
| Other market(s): | New York Stock Exchange |
| Temporary market maker: | RBC Capital Markets |
| Security ownership registration: | Uncertificated Issue – Non-Certificated Inventory |
| Investor relations: | Arthur Shannon (514) 856-3855 Email: arthur.shannon@bauschhealth.com and Lainie Keller (908) 927-1198 Email: lainie.keller@bauschhealth.com |
| Incorporation: | Canada Business Corporations Act |
| Fiscal year end: | December 31 |
| Nature of business: | The Company is a global eye health company dedicated to protecting and enhancing the gift of sight. |
| Transfer agent and registrar: | TSX Trust Company at its principal office in Toronto |
| Dividends: | The Company does not expect to pay dividends on its Common Shares for the foreseeable future. |
| Sponsorship: | Not applicable |
| Disclosure document: | Supplemented PREP prospectus dated May 5, 2022, which is available at . Capitalized terms not otherwise defined herein are as defined in the disclosure document. |
| Initial public offering: | The Offering will consist of an initial public offering by way of secondary offering of 35,000,000 Common Shares, at a price of US$18.00 per Common Share (the "Offering Price") for gross proceeds to the Selling Shareholder of US$630,000,000. In addition, the Selling Shareholder has granted the Underwriters an over-allotment option pursuant to which the Underwriters may purchase up to 5,250,000 additional Common Shares at the Offering Price. |
| Additional information: | Please refer to TSX Bulletin 2022-0353 dated May 4, 2022 and the TSX Trader Note issued at 8:44 a.m. (Toronto time) on Friday, May 6, 2022 for more information regarding the commencement of trading of BLCO on an "if, as and when issued" basis. |
| TSX contact: | Anne Child, Director, TSX Listings |